Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantationTobias Feuchtinger, Hermann Einsele, Kathrin Opherk et al.|Blood|2010Cited by 430
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic MalignanciesMohamed L. Sorror, Rainer Storb, Ginna G. Laport et al.|JAMA|2011Cited by 320
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Simona Iacobelli et al.|Journal of Clinical Oncology|2017Cited by 248
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeAnn‐Christin Pecher, Claudia Lengerke, Luca Hensen et al.|JAMA|2023Cited by 234
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell TransplantationRainer Storb, Brenda M. Sandmaier, Boglarka Gyurkocza et al.|Journal of Clinical Oncology|2013Cited by 212